Status:
WITHDRAWN
A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes
Lead Sponsor:
Eli Lilly and Company
Conditions:
Type 1 Diabetes
Type 2 Diabetes
Eligibility:
All Genders
25-75 years
Brief Summary
The main purpose of this study is to determine whether combining meal, glucose and insulin data in a web-based system will improve management of type 1 (T1D) and type 2 diabetes (T2D). No study drug w...
Eligibility Criteria
Inclusion
- Individuals with type 1 or type 2 diabetes for \>3 years by clinical diagnosis who use basal insulin, in addition to at least one injection of meal time insulin per day
- Insulin pen use for at least 3 months
- Current use of or willingness to use Dexcom G6 at least 6 out of 7 days per week
- A1c 6.5-9.5%
Exclusion
- Currently using any form of insulin pump, including hybrid closed-loop system (e.g., Medtronic 670G)
- Individuals requiring single insulin boluses of \>40 units
- Individuals planning to follow a specific diet plan for weight loss
- Inability to consume regular, consistent meals
- Individuals who have had severe hypoglycemia with seizure or coma within the past 6 months
- Individuals who have been hospitalized for diabetic ketoacidosis (DKA) within the past 6 months
Key Trial Info
Start Date :
January 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 6 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04667182
Start Date
January 25 2021
End Date
December 6 2021
Last Update
September 17 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston Medical Center
Boston, Massachusetts, United States, 02118
2
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, United States, 27599